

## Original research article

## Studying the Relationship Between Serum C-reactive Protein and Disease Severity in COPD Patients: a Prospective Study

Dr. Pankaj Mohan Shrivastava<sup>1</sup>, Dr. Mani Shankar<sup>2</sup>, Dr. Sanjeev Kumar<sup>3</sup>

<sup>1</sup>Associate Professor, Department of Medicine, Darbhanga Medical College and Hospital, Laheriasarai, Darbhanga, Bihar, India.

<sup>2</sup>Assistant Professor, Department of Pediatrics, Darbhanga Medical College and Hospital, Laheriasarai, Darbhanga, Bihar, India.

<sup>3</sup>Associate Professor, Department of General Surgery, Madhubani Medical College and Hospital, Madhubani, Bihar, India.

Corresponding Author: Dr. Sanjeev Kumar

### Abstract

**Aim:** Evaluating serum C-reactive protein level in patients with chronic obstructive pulmonary disease and its correlation with disease severity.

**Methods:** A prospective study was conducted in the Department of Medicine, Darbhanga Medical College and Hospital, Laheriasarai, Darbhanga, Bihar, India for 13 months. 50 COPD patients and 50 asymptomatic individuals were selected as the control group. COPD patients underwent spirometry tests and the severity of disease was determined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.

The main inclusion criteria for COPD patients were having symptoms or history of COPD with FEV1/FVC below 70% after using a bronchodilator.

**Results:** In this study, 100 subjects were investigated (50 patients with COPD and 50 individuals as controls). In the COPD group, 29 subjects (58%) noted cigarette smoking during the study, 9 subjects (18%) reported cigarette smoking in the past, and 17 subjects (34%) mentioned a history of baking. In the control group, 8 subjects (16%) noted cigarette smoking during the study; 4 subjects (8%) mentioned cigarette smoking in the past, and five subjects (10%) reported a history of baking. In this study, hsCRP was measured in 49 patients with COPD and 47 control subjects. The mean hsCRP was  $7519 \pm 417$  ng/mL in the COPD group and  $2874 \pm 393$  ng/mL in the control group. In the comparative study of the two groups using t-test, a significant difference was observed ( $p < 0.001$ ). The COPD group underwent spirometry and blood gas measurements, and then FEV1, FEV1%, FVC, and FEV1/FVC parameters were measured. The severity of the disease was determined by the GOLD criteria, where 16 subjects (32%) were GOLD II, 24 subjects (48%) were GOLD III, and 10 subjects (20%) were GOLD IV. There was no case of GOLD I found among the subjects because patients were hospitalized. Mean FEV1 was 1.25 L/s, mean FVC was 2.126 l, and mean FEV1/FVC was 58%.

**Conclusion:** The findings of the present study demonstrated that plasma CRP is not only effective in the evaluation of inflammation in COPD, but also useful as a marker in monitoring inflammation during COPD treatment. CRP is decreased during treatment by inhaled corticosteroids.

**Keywords:** CRP, COPD, FVC

## Introduction

COPD is a chronic inflammatory lung disease characterized by progressive airflow limitation and parenchymal destruction.<sup>1</sup> It often causes remarkable symptom burden, including chronic cough, sputum production, breathlessness, and exercise intolerance.<sup>1-3</sup> The Global Initiative for Chronic Obstructive Lung Disease guideline recommends multiple symptomatic assessments rather than just measuring breathlessness with lung function.<sup>1</sup> Among several questionnaires measuring health-related quality of life, the COPD assessment test (CAT) is widely used in routine practice.<sup>4-6</sup> It is an easy and simple measurement with an eight-item questionnaire, which is designed to quantify the impact of COPD symptoms on the patient health status with scores of 0–40.<sup>4</sup> In clinically stable COPD patients, the CAT is also closely related to the St George's Respiratory Questionnaire.<sup>7,8</sup>

C-reactive protein (CRP) is a representative systemic biomarker reflecting the total systemic burden of inflammation in individuals.<sup>9</sup> Serum CRP is elevated in stable COPD, and it correlates with disease severity and adverse health outcomes of patients with mild-to-moderate COPD.<sup>10</sup> The Copenhagen City Heart Study and Copenhagen General Population Study showed that increased levels of CRP and other systemic

biomarkers were associated with increased risk of COPD exacerbations.<sup>11</sup> CAT score is also associated with patients at high risk of exacerbation and changes significantly during and after exacerbations.<sup>6,12</sup> Moreover, an elevated CAT score at exacerbation reflects exacerbation severity.<sup>6</sup> Regarding the relationship between CAT score and CRP, change in CAT score from baseline to exacerbation onset was positively correlated to change in serum CRP.<sup>6,13</sup>

## Materials and Methods

A prospective study was conducted in the Department of Medicine, Darbhanga Medical College and Hospital, Laheriasarai, Darbhanga, Bihar, India for 13 months, after taking the approval of the protocol review committee and institutional ethics committee. 50 COPD patients and 50 asymptomatic individuals were selected as the control group. COPD patients underwent spirometry tests and the severity of disease was determined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.

The main inclusion criteria for COPD patients were having symptoms or history of COPD with FEV1/FVC below 70% after using a bronchodilator. Diseases such as hemoptysis, pneumothorax, acute coronary disease, recent MI, pulmonary embolism, vascular aneurysm, recent surgery, acute infection, history of malignancy, or any inflammatory process other than COPD, were the exclusion criteria for COPD patients. The inclusion criteria for the control group were those of age 50 years old or older, with no signs of the exclusion criteria of the COPD group, and no history of COPD, shortness of breath, or coughing.

## Procedure

In this study, all individuals in the control and COPD groups were visited, all individuals were examined, and their history taken. The information was entered into a special form. For all subjects, information such as age, sex, history of smoking, baking, medical history of the patient, as well as the vital signs, were recorded. In the COPD group, the patient's tests (including CBC and biochemistry) were examined, and if patients had any of the exclusion criteria, they were excluded. In the control group, patients were selected based on examination and history, and in case of a history of earlier diseases, they were excluded based on the exclusion criteria. In both groups, the individuals underwent blood sampling, and the serum sample of the patients was centrifuged. For each individual, 3 samples were separated to

measure hsCRP, and one sample was separated as a backup. The samples were stored at  $-20^{\circ}\text{C}$  until further use. HsCRP was measured in 47 COPD patients and 41 control patients. Due to the sensitivity of the hsCRP measurement, the hsCRP was measured three times for each sample, and the mean was considered as the averaged results of hsCRP. Serum hs-CRP was measured by immunoturbidometry assay (Roche Diagnostics, Mannheim, Germany) and an auto analyzer (Lysis, Milan, Italy), with a normal value defined as  $< 5000$  ng/L.

### Statistical analysis

Statistical analysis was carried out using SPSS 21.0 software (SPSS Inc., Chicago, IL, USA). Descriptive statistics were indicated as percent (for categorical) and mean (SD) (for continuous) variables. We used *t*-test to compare the values between groups; with  $P < 0.05$  set as the level of statistical significance.

### Results

In this study, 100 subjects were investigated (50 patients with COPD and 50 individuals as controls). The COPD group consisted of 30 men (60%) and 20 women (40%), whereas the control group was comprised of 31 men (62%) and 19 women (38%). Thus, the COPD and control groups were matched in terms of sex. There was no significant difference between these two groups. The mean age was  $65.98 \pm 11.3$  years in the COPD group and  $65.02 \pm 9.7$  years in the control group. Therefore, the COPD and control groups were matched in terms of age.

In the COPD group, 29 subjects (58%) noted cigarette smoking during the study, 9 subjects (18%) reported cigarette smoking in the past, and 17 subjects (34%) mentioned a history of baking. In the control group, 8 subjects (16%) noted cigarette smoking during the study; 4 subjects (8%) mentioned cigarette smoking in the past, and five subjects (10%) reported a history of baking. In this study, hsCRP was measured in 49 patients with COPD and 47 control subjects. The mean hsCRP was  $7519 \pm 417$  ng/mL in the COPD group and  $2874 \pm 393$  ng/mL in the control group. In the comparative study of the two groups using *t*-test, a significant difference was observed ( $p < 0.001$ ).

The COPD group underwent spirometry and blood gas measurements, and then FEV<sub>1</sub>, FEV<sub>1</sub>%, FVC, and FEV<sub>1</sub>/FVC parameters were measured. The severity of the disease was determined by the GOLD criteria, where 16 subjects (32%) were GOLD II, 24 subjects (48%) were GOLD III, and 10 subjects (20%) were GOLD IV. There was no case of GOLD I found among the subjects because patients were hospitalized. Mean FEV<sub>1</sub> was 1.25 L/s, mean FVC was 2.126 l, and mean FEV<sub>1</sub>/FVC was 58%.

The correlation between serum hsCRP and age, FEV<sub>1</sub>, PaO<sub>2</sub>, and FEV<sub>1</sub>/FVC was studied in patients with COPD, where the Pearson correlation coefficients between hsCRP and the above-mentioned variables equaled 0.181, 0.083, -0.339, and -0.051, respectively ( $P < 0.05$  in the correlation between hsCRP and FEV<sub>1</sub>, and  $P > 0.2$  in other cases).

Regarding smoking and its relationship with the severity of COPD, 29 patients reported as current smokers, where nine subjects had moderate COPD, 15 subjects had severe COPD, and two subjects had very severe COPD. In this category, there was a significant relationship between the severity of COPD and current smoking ( $P = 0.038$ ). Furthermore, 9 subjects reported as past smokers. In this group, there was a significant correlation between the severity of COPD and a history of smoking ( $P < 0.001$ ). Moreover, from among patients with COPD, 17 patients noted a history of baking. In this group, there was no significant correlation between the severity of COPD and a history of baking ( $P = 0.27$ ). The correlation between hsCRP in

patients with COPD was  $r=0.031$ , and the correlation between hsCRP in the control group was  $r=0.001$ .

The correlation between the severity of COPD and hsCRP equaled  $r=0.325$  ( $P=0.041$ ). Therefore, there is a significant correlation between the severity of COPD and hsCRP. There is also a significant correlation between hsCRP and the severity of COPD

**Table 1: Demographic characteristics and studied variables among COPD patients and asymptomatic individuals (control group)**

Variables	Control	COPD	P-value
<b>Age</b>	65.02±9.7	65.98±4.10	0.59
<b>Gender</b>			
Male	31(62%)	30(60%)	
Female	19(38%)	20(40%)	
<b>Smoking</b>			
Now smoking	8 (16%)	29(58%)	
Past smoking	4 (8%)	9 (18%)	
Baking	5 (10%)	17 (34%)	
<b>Lung Function</b>			
FEV1/L	-	1.25	
FVC/L	-	2.126	
FEV1/FVC	-	58%	
<b>hcCRP (mmol/L)</b>	4287±393	7519±417	0.001*

\* $P<0.05$ ; statistically significant

**Table 2: Smoking and its relationship with severity of COPD**

Moderate No. (%)		COPD severity Severe No. (%)	Very severe No. (%)	Total	P-value
Now smoking	12 (41.38)	15(51.72)	2 (6.89)	29	0.042
Past smoking	-	1(11.11)	8 (88.89)	9	<0.001*
Baking	6(35.29)	10 (58.82)	1 (5.88)	17	0.243

$P<0.05$ ; statistically significant

## Discussion

In this study, serum hsCRP level was measured in COPD patients and control subjects, and the correlation between partial pressure of oxygen ( $\text{PaO}_2$ ), FEV1, and age was examined with the above- mentioned blood factor. Serum CRP (SCR) is a risk factor for cardiovascular and thromboembolic diseases<sup>14</sup>, and in patients with COPD, the pulmonary inflammation apparently leads to systemic inflammation because the use of inhaled corticosteroids in these patients has been associated with a decrease in SCR and other markers of systemic inflammation.<sup>15</sup> It is observed that in these patients,  $\text{SCR}>3$  mg/L is associated with a ten-year increase in mortality.<sup>16</sup>

In this study, the hsCRP level was measured for the control and COPD groups. CRP increases the risk of thrombotic events and cardiovascular mortality. In the lungs, CRP has a protective function against bacteria and apoptotic cells in the form of an intrinsic immune system. At first, CRP is produced by hepatocytes in the liver in response to IL-6, and then enters the lungs through the plasma. The inflammation in COPD activates epithelial cells and increases alveolar macrophages and other inflammatory cells which are responsible for the release of IL-6. This in turn leads to an acute phase response and an increase in plasma CRP. Moreover, IL-6

regulates two other acute phase reactors, namely fibrinogen and  $\alpha_1$ -anti trypsin, both of which affect the pathogenesis of COPD.<sup>16,17</sup> In further support of IL-6 in the development of COPD, studies have revealed that IL-6 increases the number of CD8 and CD4 cells, macrophages, B cells, and pulmonary neutrophils, which are matched with changes seen in the pathology of COPD. On the other hand, an increase in IL-6 leads to airspace enlargement in emphysema, peribronchial accumulations, monocellular cells, increased wall thickness of airways, sub-epithelial fibrosis, and increased airway response. In animals, a contact with ozone decreases IL-6 and, consequently, reduces pulmonary injury. Therefore, plasma CRP is associated with IL-6-dependent processes in airways, leading to the progress of COPD and severe clinical problems.<sup>16,17</sup>

In this study, to eliminate the role of infection in increasing CRP, all patients with abnormal CXR (indicating pneumonia) who were febrile or had leukocytosis were excluded. In this study, consistent with the study by Tores *et al.* (2006), in Spain, and Seemungal *et al.* (2007), the mean hsCRP level between control group and COPD group was different by greater than 3.3 mg/L, which was significant ( $P < 0.001$ ).<sup>18,19</sup> A significant negative correlation between hsCRP and FEV1% was found in this research study ( $r = 0.31$ ,  $P = 0.4$ ). A similar correlation was also reported between FEV1% and hsCRP by Fimognari *et al.* (2007) ( $r = 0.37$ ,  $P = 0.01$ ), which is also consistent with the results from a study by Seemungal *et al.* (2009).<sup>18,20</sup>

### Conclusion

The findings of the present study demonstrated that plasma CRP is not only effective in the evaluation of inflammation in COPD, but also useful as a marker in monitoring inflammation during COPD treatment. CRP is decreased during treatment by inhaled corticosteroids. Moreover, the evaluation of the possible deficiency of vitamin B12 and folic acid is recommended in patients with COPD, in addition to the evaluation of the serum level of IL-6 in patients with COPD exacerbation. Furthermore, evaluating nutritional status, BMI, and serum albumin and their correlation with the outcome of the disease is required in patients with COPD.

### References

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2016. Available from: <http://www.goldcopd.org>. Accessed May 1, 2016.
2. Kim V, Criner GJ. The chronic bronchitis phenotype in chronic obstructive pulmonary disease: features and implications. *Curr Opin Pulm Med.* 2015;21(2):133–141.
3. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 1998;158(5 Pt 1):1557–1565.
4. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. *Eur Respir J.* 2009;34(3):648–654.
5. Jones PW. COPD assessment test – rationale, development, validation and performance. *COPD.* 2013;10(2):269–271.
6. Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. *Am J Respir Crit Care Med.* 2012;185(11):1218–1224.
7. Jones PW, Brusselle G, Dal Negro RW, et al. Properties of the COPD assessment test in a cross-sectional European study. *Eur Respir J.* 2011; 38(1):29–35.

8. Hwang YI, Jung KS, Lim SY, Lee YS, Kwon NH. A validation study for the Korean version of chronic obstructive pulmonary disease assessment test (CAT). *Tuberc Respir Dis (Seoul)*. 2013;74(6):256–263.
9. Black S, Kushner I, Samols D. C-reactive protein. *J Biol Chem*. 2004; 279(47):48487–48490.
10. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. *Thorax*. 2006;61(10):849–853.
11. Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. *JAMA*. 2013;309(22):2353–2361.
12. Jones PW, Harding G, Wiklund I, et al. Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. *Chest*. 2012;142(1):134–140.
13. Tu YH, Zhang Y, Fei GH. Utility of the CAT in the therapy assessment of COPD exacerbations in China. *BMC Pulm Med*. 2014;14:42
14. Zakai NA, Katz R, Jenny NS, Psaty BM, Reiner AP, SM S, et al. Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study. *Journal of thrombosis and haemostasis*. 2007;5:1128–1135.
15. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*. 2004;170:760–5
16. Dahl M, rgen Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, rge G Nordestgaard B. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*. 2007;175:250–255.
17. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. *Chest*. 2007;131:1058–67.
18. Seemungal TA, Lun JC, Davis G, Neblett C, Chinyepi N, Dookhan C. Plasma homocysteine is elevated in COPD patients and is related to COPD severity. *International Journal of Chronic Obstructive Pulmonary Disease*. 2007;2:313–21.
19. de Torres JP, Cordoba-Lanus E, López-Aguilar C, de Fuentes MM, de Garcini AM, Aguirre-Jaime A. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. *The European Respiratory Journal*. 2006;27:902–7.
20. Fimognari FL, Loffredo L, Simone SD, Sampietro F, Pastorelli R, Monaldo M, et al. Hyperhomocysteinaemia and poor vitamin B status in chronic obstructive pulmonary disease. *Nutrition, Metabolism and Cardiovascular Diseases*. 2009;19:654–659

Received: 03-05-2021 // Revised: 26-05-2021 // Accepted: 25-06-2021